GlassScriptPhysician profile
Bola Adamolekun
NPI 1104816990
$20,260.63
in general payments reported to CMS, 2019-2025
30 companies · $835 in 2025
The $835 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,053 · 2020: $7,492 · 2021: $3,179 · 2022: $1,382 · 2023: $53.90 · 2024: $2,265 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Travel and Lodging: $935 · Food and Beverage: $719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Travel and Lodging | $934.77 |
| Food and Beverage | $718.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $5,758.79 | 2019-2021 | |
| Allergan, INC. | $5,287.77 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $3,450.00 | 2021-2025 | |
| Sk Life Science, INC. | $2,242.72 | 2020-2021 | |
| Livanova USA, INC. | $1,414.35 | 2020-2024 | Vns Therapy |
| Sunovion Pharmaceuticals INC. | $374.81 | 2019-2021 | |
| Abbvie INC. | $290.91 | 2021-2023 | Vraylar, Botox |
| Novartis Pharmaceuticals Corporation | $256.13 | 2019-2024 | |
| Ucb, INC. | $226.81 | 2019-2024 | Briviact |
| Eisai INC. | $197.94 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $147.94 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $121.37 | 2020-2021 | |
| Penumbra, INC. | $84.61 | 2025 | Penumbra System |
| Biogen, INC. | $70.85 | 2019-2021 | |
| Emd Serono, INC. | $48.40 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45.35 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $29.97 | 2021 | |
| Lilly USA, LLC | $24.71 | 2019-2020 | |
| Genzyme Corporation | $23.11 | 2019 | |
| Boston Scientific Corporation | $22.17 | 2022 | |
| Abbott Laboratories | $19.34 | 2022 | |
| Arbor Pharmaceuticals, INC. | $18.40 | 2021 | |
| Avanir Pharmaceuticals, INC. | $17.61 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $16.69 | 2019 | |
| Amneal Pharmaceuticals LLC | $15.56 | 2021 | |
| Csl Behring | $15.48 | 2020 | |
| Tanabe Pharma America, INC. | $14.52 | 2021 | |
| Horizon Therapeutics Plc | $12.62 | 2021 | |
| Ge Healthcare | $11.70 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bola Adamolekun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.